Incretin Atlas › Molecules › Zovaglutide
Zovaglutide
GLP-1 (ultra-long-acting, monthly) · s.c. · QL Biopharm
Summary
- Also known as
- ZT002, QL Biopharm
- Mechanism
- GLP-1 (ultra-long-acting, monthly)
- Route
- s.c.
- Company
- QL Biopharm
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 in obesity (HORIZON-1, China, started Jan 2026) verify
- Next milestone
- HORIZON-1 readout
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 3 HORIZON-1 (China) ongoing; phase 2 met its primary endpoint (company, 2025) | HORIZON-1 |
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Registered trials (1)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| HORIZON-1 A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) | Obesity | Phase 3 | active not recruiting | 2026-01 → 2027-05 | 755 | active not recruiting | NCT07230119 |
Primary sources
No source recorded.
How to cite this page
Medical Adviser's Group. Incretin Atlas: Zovaglutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/zovaglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.